Optimization of Potent Ligands for the E3 Ligase DCAF15 and Evaluation of Their Use in Heterobifunctional Degraders
Journal of Medicinal Chemistry · 11.04.2024 · 67 (7) · 5538-5566
DOI: 10.1021/acs.jmedchem.3c02136 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 21.03.2024. Verfasst von Simon C C Lucas und 20 weiteren Autor:innen. Beteiligte Einrichtung: Hit Discovery, Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K. Hauptthemen laut MEDLINE: Ubiquitin-Protein Ligases, Nuclear Proteins. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 71 Literaturangaben.
Abstract (Originalsprache)
Unlocking novel E3 ligases for use in heterobifunctional PROTAC degraders is of high importance to the pharmaceutical industry. Over-reliance on the current suite of ligands used to recruit E3 ligases could limit the potential of their application. To address this, potent ligands for DCAF15 were optimized using cryo-EM supported, structure-based design to improve on micromolar starting points. A potent binder, compound 24, was identified and subsequently conjugated into PROTACs against multiple targets. Following attempts on degrading a number of proteins using DCAF15 recruiting PROTACs, only degradation of BRD4 was observed. Deconvolution of the mechanism of action showed that this degradation was not mediated by DCAF15, thereby highlighting both the challenges faced when trying to expand the toolbox of validated E3 ligase ligands for use in PROTAC degraders and the pitfalls of using BRD4 as a model substrate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hit Discovery, Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K.
- Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K.
- Oncology Chemistry, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.
- Mechanistic and Structural Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg SE-431 83,Sweden.
- Mechanistic and Structural Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K.
- Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, People's Republic of China.
ORCID-Profile: Simon C C Lucas, Argyrides Argyrou, Matthias R Bauer, Sylvain Demanze, Ganesh Kadamur, Iacovos N Michaelides, Monica C Rodrigo-Brenni
Zitieren
APA
Lucas, S. C. C., Ahmed, A., Ashraf, S. N., Argyrou, A., Bauer, M. R., De Donatis, G. M., Demanze, S., Eisele, F., Fusani, L., Hock, A., Kadamur, G., Li, S., Macmillan-Jones, A., Michaelides, I. N., Phillips, C., Rehnström, M., Richter, M., Rodrigo-Brenni, M. C., Shilliday, F., …, & Storer, R. I. (2024). Optimization of Potent Ligands for the E3 Ligase DCAF15 and Evaluation of Their Use in Heterobifunctional Degraders. Journal of Medicinal Chemistry, 67(7), 5538-5566. https://doi.org/10.1021/acs.jmedchem.3c02136
Vancouver
Lucas SCC, Ahmed A, Ashraf SN, Argyrou A, Bauer MR, De Donatis GM, et al. Optimization of Potent Ligands for the E3 Ligase DCAF15 and Evaluation of Their Use in Heterobifunctional Degraders. Journal of Medicinal Chemistry. 2024;67(7):5538-5566. doi:10.1021/acs.jmedchem.3c02136
BibTeX
@article{Lucas2024,
author = {Lucas, Simon C C and Ahmed, Afshan and Ashraf, S Neha and Argyrou, Argyrides and Bauer, Matthias R and De Donatis, Gian Marco and Demanze, Sylvain and Eisele, Frederik and Fusani, Lucia and Hock, Andreas and Kadamur, Ganesh and Li, Shuyou and Macmillan-Jones, Abigail and Michaelides, Iacovos N and Phillips, Christopher and Rehnström, Marie and Richter, Magdalena and Rodrigo-Brenni, Monica C and Shilliday, Fiona and Wang, Peng and Storer, R Ian},
title = {Optimization of Potent Ligands for the E3 Ligase DCAF15 and Evaluation of Their Use in Heterobifunctional Degraders},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {7},
pages = {5538--5566},
doi = {10.1021/acs.jmedchem.3c02136}
}
EUVIMED